Olema Oncology 已宣布与拜耳公司达成一项临床试验合作与供应协议。双方将共同评估其候选药物 Op-3136 与拜耳的 Nubeqa®(达洛鲁胺)联合疗法,用于治疗转移性去势抵抗性前列腺癌(mCRPC)。
Olema Oncology 已宣布与拜耳公司达成一项临床试验合作与供应协议。双方将共同评估其候选药物 Op-3136 与拜耳的 Nubeqa®(达洛鲁胺)联合疗法,用于治疗转移性去势抵抗性前列腺癌(mCRPC)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.